Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
In the phase 2 UNICORN trial, a short course of neoadjuvant botensilimab and balstilimab achieved the primary endpoint of pathological major response rate in patients with pMMR or dMMR colon cancer.